Lablanche J M, Bauters C, McFadden E P, Quandalle P, Bertrand M E
Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Lille, France.
Eur Heart J. 1993 Jul;14 Suppl B:22-4. doi: 10.1093/eurheartj/14.suppl_b.22.
Activation of potassium channels induces relaxation of vascular smooth muscle, and experimental studies have demonstrated that potassium channel activators have potent coronary vasodilator properties. In humans, nicorandil, a potassium channel blocker, causes vasodilatation not only in angiographically normal segments but also at sites of dynamic coronary stenosis, where coronary spasm has been provoked by methylergometrine as well as at sites of spontaneous spasm. The efficacy of nicorandil in relieving ergometrine-induced spasm is comparable to that of nifedipine. Oral administration of nicorandil significantly reduces the frequency of anginal episodes in patients with vasospastic angina, and either as monotherapy, or in conjunction with other agents is a novel therapeutic option in patients with vasospastic angina.
钾通道的激活可诱导血管平滑肌舒张，实验研究表明钾通道激活剂具有强大的冠状动脉舒张特性。在人类中，尼可地尔作为一种钾通道阻滞剂，不仅能使血管造影正常的节段血管扩张，还能使动态冠状动脉狭窄部位、麦角新碱诱发冠状动脉痉挛的部位以及自发性痉挛部位的血管扩张。尼可地尔缓解麦角新碱诱发痉挛的疗效与硝苯地平相当。口服尼可地尔可显著降低血管痉挛性心绞痛患者的心绞痛发作频率，无论是作为单一疗法还是与其他药物联合使用，都是血管痉挛性心绞痛患者的一种新型治疗选择。
